TetraLogic Pharmaceuticals Appoints C. Glenn Begley as Senior Vice President Research and Development

Published: Mar 15, 2012

MALVERN, Pa.--(BUSINESS WIRE)--TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the appointment of C. Glenn Begley, PhD, F.R.A.C.P., F.R.C.P.A., F.R.C.Path., as senior vice president of research and development.

Back to news